AVE (ASE:AVE)
Historical Stock Chart
From Jun 2019 to Jun 2024
Sanofi-Synthelabo's Offer for Aventis
Request for Additional Information from the Federal Trade Commission
PARIS, May 5 /PRNewswire-FirstCall/ -- As previously disclosed, Sanofi-
Synthelabo has engaged in a dialogue with the FTC on its offer for Aventis
since December 2003. Sanofi-Synthelabo has fully cooperated with the FTC's
investigation. As has been previously reported, Sanofi-Synthelabo has agreed
to divest Arixtra and Fraxiparine to GlaxoSmithKline with the condition of the
success of the offer to resolve an FTC concern.
On April 26, 2004, Sanofi-Synthelabo announced an increased offer, which has
been recommended by Aventis Supervisory Board. This increased offer is not
subject to the condition precedent of the expiration or termination of the
applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements
Act.
Sanofi-Synthelabo's Hart-Scott-Rodino notification form was filed with the FTC
on April 5, 2004 and the initial 30-day HSR waiting period expires on May 5,
2004. As is standard practice when investigating a friendly transaction of
this significance, the FTC has today issued a "second request" for information
to enable it to complete its ongoing investigation of Sanofi-Synthelabo's
offer.
Sanofi-Synthelabo and Aventis will fully cooperate with the FTC's investigation
to resolve all remaining issues as promptly as possible.
Sanofi-Synthelabo does not expect that resolution of the issues being discussed
with the FTC will have any material impact on the business of the future group.
Sanofi-Synthelabo does not expect the FTC's issuance of the second request to
delay or otherwise affect the completion of its exchange offer for Aventis,
which is expected to occur on or before the end of the second quarter of 2004.
In accordance with article 7 of the COB rule no. 2002-04, this document was
transmitted to the Autorite des marches financiers (AMF) before its
publication.
Important Information: In connection with the proposed acquisition of Aventis,
Sanofi-Synthelabo has filed a registration statement on Form F-4 (File no.
333-112314), including a prospectus/offer to exchange, and will file additional
documents with the United States Securities and Exchange Commission (SEC)
Investors are urged to read the registration statement, including the
prospectus/offer to exchange, and any other relevant documents filed with the
SEC, including all amendments and supplements (including any supplement
relating to its revised offers), because they contain important information.
Free copies of the registration statement, as well as other relevant documents
filed with the SEC, may be obtained at the SEC's web site at
http://www.sec.gov/. The prospectus/offer to exchange and other
transaction-related documents are being mailed to Aventis securityholders
eligible to participate in the U.S. offer and additional copies may be obtained
for free from MacKenzie Partners, Inc., the information agent for the U.S.
offer, at the following address: 105, Madison Avenue, New York, New York 10016;
telephone 1-(212) 929-5500 (call collect) or 1-(800) 322-2885 (toll-free call);
e-mail . In connection with its revised offer, Sanofi- Synthelabo intends to
distribute a supplement to the prospectus/offer to exchnage as soon as
practicable.
In France, holders of Aventis securities are requested, with respect to the
offer, to refer to the prospectus (note d'information), which has been granted
visa number 04-0090 by the AMFand which is available on the website of the AMF
(http://www.amf-france.org/) and without cost from: BNP Paribas Securities
Services, GIS-Emetteurs, Service Logistique, Les Collines de l'Arche, 75450
Paris Cedex 9 and to all other appropriate documents relating to the French
offer filed with the AMF.
The public offer to holders of Aventis ordinary shares located in Germany (the
"German Offer") is being made in accordance with applicable German law and
pursuant to an offer document/sales prospectus, which is available free of
charge at BNP Paribas Securities Services, Gruneburgweg 14, D-60322 Frankfurt
am Main (Fax: 069 - 152 05 277) and on the website of the Company
(http://www.sanofi-synthelabo.com/). Any decision to tender Aventis ordinary
shares in exchange for Sanofi-Synthelabo ordinary shares under the German Offer
must be taken exclusively with regard to the terms and conditions of the German
Offer, as well as with regard to the information included in the offer
document/sales prospectus, including any amendments thereto, issued in Germany.
The French Offer, the U.S. Offer and the German Offer are being made on
substantially the same terms and completion of these offers is subject to the
same conditions. It is intended that the three offers will expire at the same
time.
Investors and security holders may obtain a free copy of the Form 20-F filed
with the SEC on April 2, 2004 and any other documents filed by Sanofi-
Synthelabo with the SEC at http://www.sec.gov/ as well as of the Reference
Document filed with the AMF on April 2, 2004 (No. 04-0391) at
http://www.amf-france.org/ or directly from Sanofi-Synthelabo on our web site
at: http://www.sanofi-synthelabo.com/.
DATASOURCE: Sanofi-Synthelabo
CONTACT: Jean-Marc Podvin, Vice President, Media Relations, of Sanofi-
Synthelabo, +331-53-77-4223
Web site: http://www.sanofi-synthelabo.us/
Company News On-Call: http://www.prnewswire.com/comp/232375.html